The American Headache Society (AHS) Annual Scientific Meeting is designed for physicians, psychologists, scientists, researchers, physician assistants, nurse practitioners, and other health professionals involved in the care of patients with head, neck, and orofacial pain. It aims to disseminate the most up-to-date research and scientific advances underlying the practice of headache medicine.
Jessica Ailani, MD: Lowering the Opioid Use Rates in Migraine
July 18th 2019The director of the MedStar Georgetown Headache Center spoke about the higher-than-desired rates of opioid prescriptions for patients with migraine, and how new treatment options and provider education can help lower those numbers.
Susan Hutchinson, MD: The Potential of the Gepant Class in Acute Migraine
July 17th 2019The director of the Orange County Migraine and Headache Center spoke about the adherence issues in acute migraine treatment and how the safety profile of investigational medications such as rimegepant and ubrogepant suggests they may be able to address them.
Can Mindfulness-Based Cognitive Therapy Reduce Episodic Migraine Severity and Disability?
July 17th 2019Lead author Elizabeth K. Seng, PhD, shared insight into the findings of an exploration of the use of mindfulness-based cognitive therapy to reduce the impact of migraine on patients, as measured by Migraine Disability Assessment, as well as Headache Disability Inventory scores.
Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors
July 14th 2019The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.
Dawn Buse, PhD: Where Are Patients With Migraine Seeking Care?
July 13th 2019The clinical professor of neurology at Albert Einstein College of Medicine spoke about the trends revealed by the OVERCOME study, and how this data can be used to improve the management of the millions of patients with migraine in the US.
Richard Lipton, MD: Eptinezumab Maintains Reductions in the Impact of Migraine
July 13th 2019The director of the Montefiore Headache Center and professor of neurology at Albert Einstein College of Medicine spoke about the results of an analysis of eptinezumab’s effect on the severity of migraine and its impact on patients’ lives.
Real-World Erenumab Data Shows High Use in Chronic Migraine and Persistence to Therapy
July 13th 2019Real-world data of erenumab indicates that a large number of patients are the chronic migraine population, and there is a high rate of persistence to the anti-CGRP therapy. The most commonly prescribed dose of erenumab was 70 mg.
Low-Dose DFN-11 Successful in Relieving Severe and Moderate Acute Migraine Pain
July 13th 2019Patients with migraine who reported both moderate and severe pain intensity during headache attacks experienced high rates of relief and freedom from pain and their most bothersome symptom when treated with 3-mg sumatriptan injection, DFN-11.
HIT-6 Questionnaire Relevant and Useful in Migraine Assessments
July 12th 2019Despite ongoing discussion regarding the 6-item Headache Impact Test’s relevance in the migraine population—for which it was not specifically developed—the test has been shown to be a useful tool in the assessment of patients with migraine.
Opioid Use Remains High in Acute Migraine Settings
July 11th 2019Survey data revealed 36% of patients with migraine with prescription medications were using opioids in acute management, though data also reinforced that receiving a diagnosis of migraine or chronic migraine was associated with a significantly decreased likelihood of opioid use.
Mindfulness-Based Cognitive Therapy Excels in Episodic Migraine
July 11th 2019As measured with the Migraine Disability Assessment, the proportion of patients with episodic migraine experiencing severe disability was reduced significantly, and Headache Disability Inventory scores were significantly reduced.